Business Wire

AMAZFIT

Share
Kelvin Kiptum Breaks Limits With Amazfit

Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), a health technology company, has today announced its groundbreaking partnership with Kelvin Kiptum, the men's marathon world record holder and only athlete to complete a marathon in under two hours and one minute. As Amazfit’s ambassador, Kiptum will utilize the Amazfit Cheetah Pro to manage training and races, and the Amazfit Helio Ring to optimize recovery, ahead of marathon races in Rotterdam and Paris.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201514405/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Amazfit ambassador Kelvin Kiptum set to break marathon world record (Graphic: Business Wire)

Zepp Health expressed enthusiasm for this dynamic partnership. Pengtao Yu, VP of Industrial Design, Brand & Consumer Marketing, stated: "We are thrilled about the collaboration between Amazfit and Kelvin Kiptum. As a health technology company, we are proud to support Kelvin's quest to break records and inspire individuals worldwide to pursue their own health and fitness goals. This partnership is a testament to our commitment to empowering people to lead healthier lives through intelligent healthcare fitness solutions."

Kelvin's recent marathon achievement in Chicago, clocking a remarkable 2:00:35, sets the stage for an extraordinary collaboration. Conquering recent marathons in Valencia and London, the 24-year-old runner aims to shatter the 2-hour mark in Rotterdam this April, and clinch gold at the 2024 Olympics in Paris.

To aid his preparation, Kelvin will wear Amazfit’s Cheetah Pro. This specialist running watch features MaxTrack™ dual-band circularly-polarized GPS antenna, with 99.5% the accuracy of a professional GPS locator, along with the innovative Zepp Coach™ - an AI solution generating tailored plans for athletes looking for optimal marathon preparation. This cutting-edge technology will support Kelvin as he hones the finer details of his training.

Kelvin Kiptum shares his excitement about the collaboration, stating, "Teaming up with Amazfit for this groundbreaking journey is truly exciting. The Amazfit Cheetah Pro has become an integral part of my training regimen. As I aim to break the 2-hour mark in Rotterdam and pursue gold at the Paris Olympics, I am confident that Amazfit will be my ultimate ally in pushing the limits of human potential. Together, we are set to redefine what's possible."

This partnership extends beyond the track, with Kiptum also utilizing recently-announced Amazfit Helio Ring to take control of his recovery, with in-depth analysis of sleep quality, mental and physical Readiness, and emotional state enabled by the smart ring's BioTracker™ and EDA sensors.

The symbiosis between Amazfit and Kelvin Kiptum is emblematic of a shared commitment to breaking limits. Just as the brand's smartwatch and smart-ring are crafted for athletes seeking to push boundaries with the support of cutting-edge technology, Kelvin Kiptum continuously exemplifies the limitless potential of human ability.

By forging strategic partnerships with elite athletes like Kelvin Kiptum, Amazfit aims to create a platform that transcends geographical boundaries, providing valuable insights into performance, training, and endurance for aspiring and professional athletes.

The Amazfit Cheetah Pro is available at Amazfit.com and select retailers worldwide. The Amazfit Helio ring will be released later this spring.

For more information, visit https://www.amazfit.com/en

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201514405/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release

After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release

MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release

Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release

Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through

Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release

Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r

Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release

Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye